

Transition Metal-Free De Novo Synthesis of Sulfonated Pyrazoles from Sulfonyl Hydrazides, 1,3-Diketones, and Sodium Sulfinates at Room Temperature

Jiawen Chen,[§] Dongwei Chen,[§] Jinqiang Kuang,* and Yongmin Ma*



Cite This: *J. Org. Chem.* 2021, 86, 9289–9298



Read Online

ACCESS |




Metrics & More



Article Recommendations



Supporting Information




ABSTRACT: A transition metal-free method for de novo construction of diverse sulfonated pyrazoles from readily available sulfonyl hydrazides, 1,3-diketones, and sodium sulfinates was established under mild conditions. Pyrazoles bearing two different sulfonyl groups were obtained in one step. The method features a diversity of substituents of the pyrazole products and a remarkably simple work-up.

INTRODUCTION


Pyrazole skeletons have gained considerable attention due to their wide existence in pharmaceuticals and biologically active compounds,¹ which shows a variety of bioactivities, e.g. antimicrobial,² anticancer,³ antiinflammatory,⁴ antiproliferation,⁵ agricultural insecticide,⁶ and antioxidation activity.⁷ Besides, pyrazoles also play important roles in coordinating chemistry, organometallic chemistry, and latent fingerprints analysis.⁸ In addition, substituents on the pyrazole skeleton might also play important roles in the activities. At this point, it is meaningful to develop efficient methods for constructing pyrazoles bearing diverse functional groups.⁹ Sulfone groups, often uncovered in biologically active molecules, agrochemicals, and materials, constitute one of the most valuable sorts of organic functional groups.¹⁰ Incorporation of sulfone group into particular skeletons is a frequently used strategy to gain better activities during the drug design.¹¹ Given these viewpoints, the synthesis of sulfonated pyrazoles has evoked lots of interest from synthetic chemists.^{12–15}

Conventional approaches targeting this consist of cycloaddition of reagents in which sulfone groups were pre-installed and remained untouched during the reaction and oxidation of pyrazoles with thioether groups.^{12,13} In 2014, Wan et al. reported the pioneering synthesis of sulfonated pyrazoles from sulfonyl hydrazides and 1,3-diketones, in which sulfonyl hydrazides function as both the ring component and sulfonyl precursor (eq 1).^{14a} Recently, this dual-role-sulfonyl-hydrazide

Previous work:



This work:



Received: January 22, 2021

Published: June 29, 2021



Table 1. Optimization of Reaction Conditions^a

TsNHNH_2 + $\text{CH}_3\text{COCH}_2\text{COCH}_3$ + PhSO_2Na $\xrightarrow[\text{solvent, rt, 22 h}]{\text{oxidant, base}}$ 4a

entry	oxidant (equiv)	solvent	base (equiv)	isolated yield (%)
1	I ₂ (2.0)	CH ₃ CN	K ₂ HPO ₄ ·3H ₂ O (1.5)	58
2	I ₂ (2.0)	EA	K ₂ HPO ₄ ·3H ₂ O (1.5)	40
3	I ₂ (2.0)	THF	K ₂ HPO ₄ ·3H ₂ O (1.5)	36
4	I ₂ (2.0)	DMSO	K ₂ HPO ₄ ·3H ₂ O (1.5)	33
5	I ₂ (2.0)	1,4-dioxane	K ₂ HPO ₄ ·3H ₂ O (1.5)	41
6	I ₂ (2.0)	DMA	K ₂ HPO ₄ ·3H ₂ O (1.5)	37
7	I ₂ (2.0)	NMP	K ₂ HPO ₄ ·3H ₂ O (1.5)	35
8	I ₂ (1.5)	CH ₃ CN	K ₂ HPO ₄ ·3H ₂ O (1.5)	57
9	I ₂ (1.1)	CH ₃ CN	K ₂ HPO ₄ ·3H ₂ O (1.5)	50
10	I ₂ (1.5)	CH ₃ CN	NaHCO ₃ (1.5)	32
11	I ₂ (1.5)	CH ₃ CN	NaOAc (1.5)	35
12	I ₂ (1.5)	CH ₃ CN	K ₂ CO ₃ (1.5)	11
13	I ₂ (1.5)	CH ₃ CN	KOH (1.5)	32
14	I ₂ (1.5)	CH ₃ CN	^t BuOK (1.5)	29
15	I ₂ (1.5)	CH ₃ CN	K ₂ HPO ₄ ·3H ₂ O (0.8)	58
16	I ₂ (1.5)	CH ₃ CN	K ₂ HPO ₄ ·3H ₂ O (0.6)	51
17	I ₂ (1.5)	CH ₃ CN	K ₂ HPO ₄ (0.8)	46
18 ^b	I ₂ (1.5)	CH ₃ CN		42
19		CH ₃ CN	K ₂ HPO ₄ (0.8)	n.d. ^c
20	I ₂ (0.2) + TBHP (3)	CH ₃ CN	K ₂ HPO ₄ ·3H ₂ O (0.8)	11
21	I ₂ (0.2) + DTBP (3)	CH ₃ CN	K ₂ HPO ₄ ·3H ₂ O (0.8)	16

^aReaction conditions: 4-methylbenzenesulfonylhydrazide (**1a**) (0.5 mmol), pentane-2,4-dione (**2a**) (0.6 mol), sodium 4-methylbenzenesulfinate (**3a**) (1.0 mol), oxidant, base, solvent (4.5 mL), air, and rt. ^bThe reaction was carried out at 35 °C. ^cn.d. = not detected.


strategy was applied to the reactions of sulfonyl hydrazides with enaminones, affording sulfonated pyrazoles under mild conditions (eq 2).^{14b,c} This strategy makes full use of the sulfonyl hydrazides involved in the reaction; however, it could only introduce two identical sulfonyl groups to the pyrazole skeleton. Compared to sulfonyl hydrazides, sodium sulfonates are more environmentally benign sulfone sources. In 2017, Wang et al. reported a molecular iodine-catalyzed direct sulfonation of preformed pyrazolones with sodium sulfonates (eq 3).¹⁵ Although these methods are inspiring, more general and efficient protocols are still much in demand to get over the existing limitations such as extra steps to prepare active precursors, applying excess amounts of organometallic reagents, harsh reaction conditions, tedious work-up procedures, and limited substrate scope or low yields. Aiming at developing a green, practical, and efficient method for constructing diverse sulfonated pyrazoles, we speculated that the target compounds might be produced from readily available 1,3-dielectrophiles, sulfonyl hydrazides, and sodium sulfonates, in which the latter two reagents might serve as the sulfonyl precursors at the same time in the reaction, giving rise to pyrazoles with more tunable structures. As a verification, we herein reported a novel strategy for the synthesis of diverse sulfonated pyrazoles through a molecular iodine-promoted multicomponent reaction of sulfonyl hydrazides, 1,3-diketones, and sodium sulfonates (eq 4).

RESULTS AND DISCUSSION


Initial reactivity assays were conducted with 4-methylbenzenesulfonylhydrazide **1a**, pentane-2,4-dione **2a**, and sodium benzenesulfinate **3a** as model substrates. To our delight, in the

presence of I₂ (2.0 equiv) and K₂HPO₄·3H₂O (1.5 equiv) in CH₃CN at room temperature, the desired pyrazole **4a** was obtained in 58% isolated yield (Table 1, entry 1). Other solvents such as ethyl acetate, tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), 1,4-dioxane, dimethylacetamide (DMA), and *N*-methyl-2-pyrrolidone (NMP) also work in the reaction, albeit providing pyrazole **4a** in inferior yields (Table 1, entries 2–7). A comparable yield of pyrazole **4a** was obtained when decreasing the loading of iodine to 1.5 equiv, while further decreasing to 1.1 equiv gave only 50% yield (Table 1, entries 8 and 9). Further investigation of other bases revealed that K₂HPO₄·3H₂O was the best choice (Table 1, entries 10–14). The optimal amount of K₂HPO₄·3H₂O was found to be 0.8 equiv, although a 42% isolated yield of **4a** was produced at 35 °C even without K₂HPO₄·3H₂O (Table 1, entries 15, 16, and 18). These results indicate that the base K₂HPO₄·3H₂O plays a promotive part in the transformation, but not an indispensable one. Iodine is essential in this transformation as the desired product **4a** was not observed in the absence of iodine (Table 1, entry 19). Applying a catalytic amount of iodine (20 mol %) and 3 equiv of additional oxidant (TBHP or DTBP) did not yield pyrazole **4a** in a satisfactory yield; only 11 and 16% yields were obtained, respectively (Table 1, entries 20 and 21).


With the optimal conditions in hand, we then examined the generality of the method by applying various sulfonyl hydrazides, 1,3-diketones, and sodium sulfonates. The scope of sulfonyl hydrazides was first investigated. As exhibited in Table 2, various aryl sulfonyl hydrazides bearing electron-donating or -withdrawing substituents were compatible in this reaction, affording pyrazoles **4a–4q** in yields of 47–67% under

Table 2. Substrate Scope of Sulfonyl Hydrazides^a

^aReaction conditions: **1** (0.5 mmol), **2a** (0.6 mmol), **3** (1.0 mmol), I₂ (0.75 mmol), K₂HPO₄·3H₂O (0.4 mmol), CH₃CN (4.5 mL), air, rt, and 22 h.

Table 3. Substrate Scope of 1,3-Diketones^a

^aReaction conditions: **1a** (0.5 mmol), **2** (0.6 mmol), **3b** (1.0 mmol), I₂ (0.75 mmol), K₂HPO₄·3H₂O (0.4 mmol), CH₃CN (4.5 mL), air, rt, and 22 h.

Table 4. Substrate Scope of Sodium Sulfonates^a


^aReaction conditions: **1a** (0.5 mmol), **2d** (0.6 mmol), **3** (1.0 mmol), I_2 (0.75 mmol), $K_2HPO_4 \cdot 3H_2O$ (0.4 mmol), CH_3CN (4.5 mL), air, rt, and 22 h. ^bSodium ethanesulfinate (2.0 mmol) was used. ^cSodium trifluoromethanesulfinate (2.0 mmol) was used.

mild reaction conditions. The electronic properties of the substituents on the aromatic ring of aryl sulfonyl hydrazides did not show much influence on yields. It is notable that the functional groups such as fluoro, chloro, bromo, iodo, nitro, and cyano were well tolerated in this transformation, allowing the further elaboration of the corresponding products. Heteroaryl sulfonyl hydrazides such as quinoline-8-sulfonylhydrazide and thiophene-2-sulfonylhydrazide were also suitable substrates in the reaction, producing the corresponding pyrazoles **4r** and **4s** in 51% yields. Remarkably, the aliphatic sulfonyl hydrazide, which was ineffective in the previous report,¹⁴ was an adaptable substrate as well in this protocol, affording pyrazole **4t** in a 45% isolated yield.

Next, the reactivity of nonsymmetrical 1,3-diketones in this reaction was surveyed with 4-methylbenzenesulfonylhydrazide (**1a**) and sodium *p*-toluenesulfinate (**3b**) under the standard conditions. As shown in Table 3, a variety of nonsymmetrical 1,3-diketones were suitable substrates in this method. When 6-methylheptane-2,4-dione was applied in the protocol, the corresponding pyrazole **4u** was produced in 70% yield and excellent regioselectivity.¹⁶ Nonane-2,4-dione, which contains a longer carbon chain, was also smoothly converted into the desired product **4v** in 56% yield under the optimal conditions. The investigation was then directed to 1,3-diketones with an aryl group. 1-Phenylbutane-1,3-dione proved to be quite active under the standard conditions, furnishing **4w** in 80% yield. In addition, 1-arylbutane-1,3-diones bearing methoxy, fluoro, chloro, and bromo substituents on the aryl ring were all compatible in the reaction, yielding the corresponding functionalized pyrazole products in 68–76% yields (Table 3, **4y** and **4A–4D**). 1,3-Diketones with a heteroaryl group such as benzo[*b*]thiophen-2-yl, 3-thiophenyl, 2-furanyl, and 2-pyridinyl suited the standard conditions as well, constructing pyrazoles **4E–4H** with two heteroaryl rings in 49–65% yields.

The generality of sodium sulfonates was examined by the reaction with 4-methylbenzenesulfonylhydrazide (**1a**) and 1-phenylbutane-1,3-dione (**2d**) (Table 4). Sodium 4-chlorobenzene sulfinate (**3c**) and sodium 4-fluorobenzene sulfinate (**3d**) were less effective than sodium *p*-toluenesulfinate (**3b**) in this method, generating the corresponding products **4I** and **4J** in 62 and 58% yield (*vs* **4w**, 80%), respectively. Encouragingly, aliphatic sodium sulfinate, e.g., sodium ethanesulfinate, was fit with the protocol as well, furnishing pyrazole **4K** in 64% yield under slightly modified conditions. The Langlois reagent (CF_3SO_2Na) also survived in the reaction; however, only 24% yield of product **4L** was obtained.

To test the practicality of the method for the synthesis of fully substituted pyrazoles, a gram-scale reaction was carried out. Under the standard conditions, the reaction of 4-methylbenzenesulfonylhydrazide (**1a**, 4.0 mmol), 1-phenylbutane-1,3-dione (**2d**, 4.8 mmol), and sodium *p*-toluenesulfinate (**3b**, 8.0 mmol) proceeded smoothly, providing 1.57 g of pyrazole **4w** in 84% yield (eq 5). It is remarkable that the pure product was obtained through a simple filtration, thus dramatically reducing the time and solvents consumed during the conventional work-up.




To gain more insight into the mechanism of the reaction, some control experiments were carried out. Under the standard conditions, the desired product **4a** was not detected when pyrazole **5** was subjected to the reaction (Scheme 1a), indicating that the reaction would probably not proceed through a cyclization–sulfonylation process. When a radical scavenger 2,6-di-*tert*-butyl-4-methylphenol (BHT) or 2,2,6,6-tetramethylpiperidine-*N*-oxyl (TEMPO) was added to the reaction system, the desired product **4a** was provided in 49 and 56% yield, respectively (Scheme 1b,c), showing little influence on the reaction effectivity. These results suggested that a radical process was not likely involved in this method.

Based on the results of control experiments, a plausible mechanism for the reaction is depicted in Scheme 2. Sulfonyl iodide **6** is easily generated from sodium sulfinate **3** and molecular iodine.^{15,17} The condensation of sulfonyl hydrazide and 1,3-diketone afforded imine **7**, which then undergoes tautomerization to produce its enol form **8**. A following nucleophilic attack of the enol form **8** toward the in situ generated sulfonyl iodide **6** yields intermediate **9**, which finally produces the desired product **4** by an intramolecular condensation.


CONCLUSIONS

To conclude, a molecular iodine-promoted transition metal-free method for the synthesis of sulfonated pyrazoles from readily available sulfonyl hydrazides, 1,3-diketones, and sodium sulfonates has been established under mild conditions. Sulfonyl hydrazides and sodium sulfonates each offer a sulfonyl group in the reaction, improving the diversity of the desired products. The protocol features broad substrate scope and easy

Scheme 1. Control Experiments



Scheme 2. Plausible Reaction Mechanism



manipulation. Considering its green conditions and simple operation, the protocol might be fairly appealing in synthetic chemistry. Further mechanistic study and elaboration of the methodology to construct other diversely substituted heterocyclic compounds is being pursued in our laboratory.

EXPERIMENTAL SECTION

General Methods. All commercially available reagents were used without further purification. Analytical TLC was performed on glass-backed plates precoated with silica gel, which were visualized by UV fluorescence ($\lambda_{\text{max}} = 254 \text{ nm}$). ¹H NMR and ¹³C NMR spectra were recorded on a Bruker 400 MHz spectrometer (¹H: 400 MHz; ¹³C: 100 MHz), using CDCl₃ as the solvent with tetramethylsilane (TMS) as an internal standard at room temperature. All ¹H NMR spectra are reported in parts per million (ppm) downfield of TMS and were measured relative to the signals at 0 ppm (TMS). All ¹³C NMR spectra were reported in ppm relative to the residual CHCl₃ (77.0 ppm) and were obtained with ¹H-decoupling. Data for ¹H NMR are described as follows: chemical shift (δ in ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet; sep, septet; m, multiplet; br, broad signal), coupling constant (Hz), integration. Data for ¹³C NMR are described in terms of chemical shift (δ in ppm). High-resolution mass spectra were recorded on an ESI-Q-TOF mass spectrometer. Melting points were measured on the X4 melting point apparatus and uncorrected.

Sulfonyl hydrazides¹⁸ and 1,3-diketones¹⁹ were prepared according to the reported procedures.

General Procedure for the Synthesis of Pyrazoles 4. To a Schlenk tube (10 mL) were added sulfonyl hydrazide (0.5 mmol), 1,3-diketone (0.6 mmol, 1.2 equiv), sodium sulfinate (1.0 mmol, 2.0 equiv), K₂HPO₄·3H₂O (0.4 mmol, 0.8 equiv), I₂ (0.75 mmol, 1.5 equiv), and 4.5 mL of CH₃CN sequentially under air. Then, the tube was sealed and the reaction mixture was stirred at room temperature

for 22 h. It was then quenched (consumption of residual I₂) with saturated Na₂S₂O₃ solution, forming a white precipitate. Filtration of the suspension gave the crude product. The crude product was washed with water (15 mL) and petroleum ether (15 mL) sequentially to afford pure product 4.

3,5-Dimethyl-4-(phenylsulfonyl)-1-tosyl-1H-pyrazole (4a). The title compound was obtained as a white solid (113.6 mg, 58%). Mp 120–122 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.90–7.83 (m, 4H), 7.61 (t, $J = 7.4 \text{ Hz}$, 1H), 7.53 (t, $J = 7.6 \text{ Hz}$, 2H), 7.37 (d, $J = 8.4 \text{ Hz}$, 2H), 2.86 (s, 3H), 2.45 (s, 3H), 2.37 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.1, 146.8, 146.5, 142.0, 133.7, 133.4, 130.2, 129.2, 128.1, 126.5, 121.3, 21.7, 21.6, 13.6, 11.6; HRMS (TOFMS) m/z [M + Na]⁺ calcd for C₁₈H₁₈N₂O₄S₂Na: 413.0606; found: 413.0610.

3,5-Dimethyl-1,4-ditosyl-1H-pyrazole (4b).^{14a,b} The title compound was obtained as a white solid (127.3 mg, 63%). Mp 123–125 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, $J = 8.4 \text{ Hz}$, 2H), 7.73 (d, $J = 8.0 \text{ Hz}$, 2H), 7.35 (d, $J = 8.4 \text{ Hz}$, 2H), 7.31 (d, $J = 8.0 \text{ Hz}$, 2H), 2.85 (s, 3H), 2.44 (s, 3H), 2.41 (s, 3H), 2.36 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.1, 146.6, 146.5, 144.5, 139.2, 133.9, 130.2, 129.9, 128.1, 126.6, 121.7, 21.7, 21.5, 13.6, 11.6.

3,5-Dimethyl-1-(phenylsulfonyl)-4-tosyl-1H-pyrazole (4c). The title compound was obtained as a white solid (116.2 mg, 59%). Mp 155–156 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, $J = 8.4 \text{ Hz}$, 2H), 7.77–7.66 (m, 3H), 7.58 (t, $J = 7.4 \text{ Hz}$, 2H), 7.31 (d, $J = 8.0 \text{ Hz}$, 2H), 2.86 (s, 3H), 2.42 (s, 3H), 2.36 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.3, 146.8, 144.5, 139.1, 136.9, 135.0, 129.9, 129.6, 128.0, 126.6, 121.9, 21.5, 13.6, 11.7; HRMS (TOFMS) m/z [M + Na]⁺ calcd for C₁₈H₁₈N₂O₄S₂Na: 413.0606; found: 413.0615.

1-[(1,1'-Biphenyl)-4-ylsulfonyl]-3,5-dimethyl-4-tosyl-1H-pyrazole (4d). The title compound was obtained as a white solid (123.3 mg, 53%). Mp 162–164 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 8.4 Hz, 2H), 7.79–7.72 (m, 4H), 7.59 (d, *J* = 8.0 Hz, 2H), 7.53–7.41 (m, 3H), 7.32 (d, *J* = 8.0 Hz, 2H), 2.89 (s, 3H), 2.42 (s, 3H), 2.38 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.4, 148.1, 146.8, 144.6, 139.2, 138.5, 135.2, 129.9, 129.1, 129.0, 128.7, 128.2, 127.4, 126.7, 121.9, 21.5, 13.7, 11.8; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₂₄H₂₂N₂O₄S₂Na: 489.0919; found: 489.0923.

3,5-Dimethyl-1-(naphthalen-2-ylsulfonyl)-4-tosyl-1H-pyrazole (4e). The title compound was obtained as a white solid (125.0 mg, 56%). Mp 148–150 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.61 (s, 1H), 8.00 (t, *J* = 9.0 Hz, 2H), 7.92 (d, *J* = 8.0 Hz, 2H), 7.83 (dd, *J* = 8.6, 1.4 Hz, 2H), 7.76–7.62 (m, 4H), 7.30 (d, *J* = 8.0 Hz, 2H), 7.53–7.41 (m, 3H), 7.32 (d, *J* = 8.0 Hz, 2H), 2.91 (s, 3H), 2.40 (s, 3H), 2.36 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.3, 146.8, 144.5, 139.1, 135.7, 133.6, 131.8, 130.4, 130.1, 130.0, 129.9, 129.6, 128.1, 128.0, 126.6, 122.0, 121.9, 21.5, 13.6, 11.8; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₂₂H₂₀N₂O₄S₂Na: 463.0762; found: 463.0765.

1-((4-Tert-butyl)phenyl)sulfonyl)-3,5-dimethyl-4-tosyl-1H-pyrazole (4f). The title compound was obtained as a white solid (114.3 mg, 51%). Mp 151–152 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, *J* = 8.8 Hz, 2H), 7.74 (d, *J* = 8.0 Hz, 2H), 7.57 (d, *J* = 8.4 Hz, 2H), 7.31 (d, *J* = 8.0 Hz, 2H), 2.84 (s, 3H), 2.41 (s, 3H), 2.37 (s, 3H), 1.34 (s, 9H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 159.3, 151.2, 146.7, 144.5, 139.2, 133.8, 129.9, 128.0, 126.69, 126.66, 121.8, 35.4, 30.9, 21.5, 13.7, 11.7; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₂₂H₂₆N₂O₄S₂Na: 469.1232; found: 469.1232.

3,5-Dimethyl-1-(*m*-tolylsulfonyl)-4-tosyl-1H-pyrazole (4g). The title compound was obtained as a white solid (132.2 mg, 66%). Mp 130–131 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.82–7.76 (m, 2H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.52–7.40 (m, 2H), 7.32 (d, *J* = 8.0 Hz, 2H), 2.85 (s, 3H), 2.44 (s, 3H), 2.42 (s, 3H), 2.37 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.2, 146.7, 144.5, 140.1, 139.2, 136.7, 135.9, 129.9, 129.4, 128.2, 126.6, 125.2, 121.8, 21.5, 21.2, 13.6, 11.7; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₁₉H₂₀N₂O₄S₂Na: 427.0762; found: 427.0767.

1-((4-Methoxyphenyl)sulfonyl)-3,5-dimethyl-4-tosyl-1H-pyrazole (4h). The title compound was obtained as a white solid (121.5 mg, 58%). Mp 132–135 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, *J* = 8.4 Hz, 2H), 7.73 (d, *J* = 8.4 Hz, 2H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.01 (d, *J* = 8.8 Hz, 2H), 3.89 (s, 3H), 2.84 (s, 3H), 2.42 (s, 3H), 2.36 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 164.8, 151.0, 146.4, 144.5, 139.3, 130.7, 129.9, 128.0, 126.7, 121.6, 114.8, 55.8, 21.5, 13.7, 11.7; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₁₉H₂₀N₂O₅S₂Na: 443.0711; found: 443.0720.

1-(Mesitylsulfonyl)-3,5-dimethyl-4-tosyl-1H-pyrazole (4i). The title compound was obtained as a white solid (132.3 mg, 61%). Mp 181–182 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 8.0 Hz, 2H), 6.99 (s, 2H), 2.82 (s, 3H), 2.53 (s, 6H), 2.42 (s, 3H), 2.31 (s, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 150.0, 146.3, 145.2, 144.4, 141.1, 139.4, 132.2, 131.3, 129.9, 126.7, 120.9, 22.5, 21.5, 21.1, 13.6, 11.5; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₂₁H₂₄N₂O₄S₂Na: 455.1075; found: 455.1084.

3,5-Dimethyl-4-tosyl-1-((2,4,6-triisopropylphenyl)sulfonyl)-1H-pyrazole (4j). The title compound was obtained as a white solid (120.8 mg, 47%). Mp 145–147 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 8.4 Hz, 2H), 7.30 (d, *J* = 8.0 Hz, 2H), 7.19 (s, 2H), 4.01 (sep, *J* = 6.7 Hz, 2H), 2.92 (sep, *J* = 6.9 Hz, 1H), 2.73 (s, 3H), 2.42 (s, 3H), 2.34 (s, 3H), 1.26 (d, *J* = 6.8 Hz, 6H), 1.13 (d, *J* = 6.8 Hz, 12H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 155.5, 152.1, 149.5, 145.5, 144.3, 139.5, 130.2, 129.8, 126.6, 124.2, 121.0, 34.2, 29.6, 24.2, 23.3, 21.5, 13.4, 13.1; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₂₇H₃₆N₂O₄S₂Na: 539.2014; found: 539.2015.

1-((4-Fluorophenyl)sulfonyl)-3,5-dimethyl-4-tosyl-1H-pyrazole (4k). The title compound was obtained as a white solid (135.5 mg, 67%). Mp 182–184 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.06–8.00 (m, 2H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.29–7.22 (m, 2H), 2.86 (s, 3H), 2.43 (s, 3H), 2.36 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 166.4 (d, *J* = 257.8 Hz), 151.5, 146.8, 144.6, 139.1, 132.9 (d, *J* = 3.9 Hz), 131.3 (d, *J* = 9.3 Hz), 129.9, 126.7, 122.0, 117.0 (d, *J* = 22.8 Hz), 21.5, 13.6, 11.7; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₁₈H₁₇N₂O₄S₂Na: 431.0511; found: 431.0517.

1-((4-Chlorophenyl)sulfonyl)-3,5-dimethyl-4-tosyl-1H-pyrazole (4l). The title compound was obtained as a white solid (140.6 mg, 66%). Mp 159–160 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, *J* = 8.4 Hz, 2H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.55 (d, *J* = 8.8 Hz, 2H), 7.32 (t, *J* = 8.0 Hz, 2H), 2.86 (s, 3H), 2.43 (s, 3H), 2.36 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.7, 146.9, 144.6, 142.0, 139.1, 135.3, 130.0, 129.6, 126.7, 122.1, 21.5, 13.7, 11.7; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₁₈H₁₇ClN₂O₄S₂Na: 447.0216; found: 447.0225.

1-((4-Bromophenyl)sulfonyl)-3,5-dimethyl-4-tosyl-1H-pyrazole (4m). The title compound was obtained as a white solid (126.7 mg, 54%). Mp 198–199 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, *J* = 8.4 Hz, 2H), 7.77–7.68 (m, 4H), 7.32 (d, *J* = 8.0 Hz, 2H), 2.85 (s, 3H), 2.42 (s, 3H), 2.36 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.7, 146.9, 144.6, 139.1, 135.8, 133.0, 130.7, 130.0, 129.6, 126.7, 122.1, 21.5, 13.7, 11.7; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₁₈H₁₇BrN₂O₄S₂Na: 490.9711; found: 490.9715.

1-((4-Iodophenyl)sulfonyl)-3,5-dimethyl-4-tosyl-1H-pyrazole (4n). The title compound was obtained as a white solid (149.2 mg, 58%). Mp 184–186 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, *J* = 8.4 Hz, 2H), 7.73 (d, *J* = 8.4 Hz, 2H), 7.68 (d, *J* = 8.8 Hz, 2H), 7.32 (d, *J* = 8.0 Hz, 2H), 2.85 (s, 3H), 2.42 (s, 3H), 2.36 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.6, 146.9, 144.6, 139.1, 138.9, 136.4, 129.9, 129.2, 126.7, 122.1, 103.5, 21.5, 13.7, 11.7; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₁₈H₁₇I₂O₄S₂Na: 538.9572; found: 538.9573.

3,5-Dimethyl-1-((4-nitrophenyl)sulfonyl)-4-tosyl-1H-pyrazole (4o). The title compound was obtained as a white solid (115.2 mg, 53%). Mp 228–230 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.41 (d, *J* = 9.2 Hz, 2H), 8.21 (d, *J* = 8.8 Hz, 2H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.73 (d, *J* = 8.0 Hz, 2H), 2.89 (s, 3H), 2.43 (s, 3H), 2.35 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 152.5, 151.3, 147.5, 144.9, 142.3, 139.0, 130.1, 129.8, 126.8, 124.8, 122.8, 21.6, 13.7, 11.8; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₁₈H₁₇N₃O₆S₂Na: 458.0456; found: 458.0459.

1-((4-Cyanophenyl)sulfonyl)-3,5-dimethyl-4-tosyl-1H-pyrazole (4p). The title compound was obtained as a white solid (130.7 mg, 63%). Mp 210–211 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J* = 8.4 Hz, 2H), 7.87 (d, *J* = 8.4 Hz, 2H), 7.74 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 2.88 (s, 3H), 2.43 (s, 3H), 2.35 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 152.3, 147.4, 144.8, 140.8, 138.9, 133.3, 130.0, 128.9, 126.8, 122.6, 118.7, 116.6, 55.8, 21.6, 13.7, 11.8; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₁₉H₁₇N₃O₄S₂Na: 438.0560; found: 438.0558.

1-(2-Chlorophenyl)sulfonyl)-3,5-dimethyl-4-tosyl-1H-pyrazole (4q). The title compound was obtained as a white solid (110.4 mg, 52%). Mp 139–141 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, *J* = 8.0 Hz, 1H), 7.75 (d, *J* = 8.4 Hz, 2H), 7.62 (td, *J* = 7.8, 1.6 Hz, 1H), 7.51 (t, *J* = 7.6 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 2.95 (s, 3H), 2.43 (s, 3H), 2.30 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.5, 148.9, 144.5, 139.3, 135.9, 134.8, 132.9, 132.4, 132.2, 129.9, 127.6, 126.6, 121.2, 21.5, 13.6, 12.1; HRMS (TOFMS) *m/z* [M + Na]⁺ calcd for C₁₈H₁₇ClN₂O₄S₂Na: 447.0216; found: 447.0219.

8-(3,5-Dimethyl-4-tosyl-1H-pyrazol-1-yl)sulfonylquinoline (4r). The title compound was obtained as a white solid (112.7 mg, 51%). Mp 204–206 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.73 (dd, *J* = 8.4, 1.6 Hz, 1H), 8.68 (dd, *J* = 7.2, 1.2 Hz, 1H), 8.22 (dd, *J* = 8.4, 1.6 Hz, 1H), 8.15 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.78–7.68 (m, 3H), 7.48 (dd, *J* = 8.4, 4.4 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 3.24 (s, 3H), 2.44 (s, 3H), 2.22 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 151.3, 151.2, 151.0, 144.2,

143.4, 139.8, 136.6, 135.7, 134.0, 133.4, 129.8, 128.7, 126.6, 125.5, 122.5, 120.5, 21.5, 13.7, 12.6; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{21}H_{19}N_3O_4S_2Na$: 464.0715; found: 464.0717.

3,5-Dimethyl-1-(thiophen-2-ylsulfonyl)-4-tosyl-1H-pyrazole (4s). The title compound was obtained as a white solid (101.3 mg, 51%). Mp 146–147 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.86 (dd, $J = 3.6, 1.2$ Hz, 1H), 7.79 (dd, $J = 4.8, 1.2$ Hz, 1H), 7.74 (d, $J = 8.4$ Hz, 2H), 7.32 (d, $J = 8.0$ Hz, 2H), 7.16 (t, $J = 4.6$ Hz, 1H), 2.88 (s, 3H), 2.43 (s, 3H), 2.38 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.5, 146.8, 144.6, 139.1, 136.4, 136.2, 135.8, 129.9, 128.1, 126.7, 122.1, 21.5, 13.7, 11.8; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{16}H_{16}N_2O_4S_3Na$: 419.0170; found: 419.0175.

3,5-Dimethyl-1-(propylsulfonyl)-4-tosyl-1H-pyrazole (4t). The title compound was obtained as a white solid (80.9 mg, 45%). Mp 97–98 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.76 (d, $J = 8.0$ Hz, 2H), 7.33 (d, $J = 8.4$ Hz, 2H), 3.51–3.42 (m, 2H), 2.83 (s, 3H), 2.43 (s, 6H), 1.83–1.71 (m, 2H), 1.04 (t, $J = 7.4$ Hz, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.4, 147.6, 144.6, 139.2, 130.0, 126.6, 121.6, 56.2, 21.5, 16.5, 13.6, 12.4, 11.5; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{15}H_{20}N_2O_4S_2Na$: 379.0762; found: 379.0762.

5-Isobutyl-3-methyl-1,4-ditosyl-1H-pyrazole (4u).^{14a} The title compound was obtained as a white solid (155.8 mg, 70%). Mp 166–167 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.87 (d, $J = 8.4$ Hz, 2H), 7.71 (d, $J = 8.0$ Hz, 2H), 7.34 (d, $J = 8.0$ Hz, 2H), 7.29 (d, $J = 8.0$ Hz, 2H), 3.29 (d, $J = 7.6$ Hz, 2H), 2.44 (s, 3H), 2.42 (s, 3H), 2.29–2.17 (m, 4H), 0.98 (s, 3H), 0.97 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.4, 151.3, 146.3, 144.3, 139.3, 134.2, 129.9, 129.7, 128.4, 126.8, 121.4, 32.8, 30.1, 22.1, 21.7, 21.5, 13.7.

3-Methyl-5-pentyl-1,4-ditosyl-1H-pyrazole (4v). The title compound was obtained as a white solid (128.8 mg, 56%). Mp 111–113 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.88 (d, $J = 8.4$ Hz, 2H), 7.73 (d, $J = 8.4$ Hz, 2H), 7.35 (d, $J = 8.0$ Hz, 2H), 7.31 (d, $J = 8.0$ Hz, 2H), 3.30–3.22 (m, 2H), 2.45 (s, 3H), 2.42 (s, 3H), 2.33 (s, 3H), 1.63–1.49 (m, 2H), 1.47–1.28 (m, 4H), 0.91 (t, $J = 7.0$ Hz, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.8, 151.3, 146.4, 144.4, 139.3, 134.1, 130.0, 129.8, 128.3, 126.8, 120.8, 31.9, 30.2, 25.4, 22.1, 21.7, 21.5, 13.9, 13.7; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{23}H_{28}N_2O_4S_2Na$: 483.1388; found: 483.1388.

3-Methyl-5-phenyl-1,4-ditosyl-1H-pyrazole (4w).^{14a,b} The title compound was obtained as a white solid (187.8 mg, 80%). Mp 184–186 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.56–7.48 (m, 3H), 7.37 (t, $J = 7.8$ Hz, 2H), 7.30–7.22 (m, 4H), 7.13–7.03 (m, 4H), 2.57 (s, 3H), 2.42 (s, 3H), 2.35 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.0, 147.8, 146.4, 144.2, 138.5, 133.8, 130.6, 130.1, 129.9, 129.3, 128.3, 127.3, 127.1, 126.2, 124.1, 21.7, 21.5, 14.0.

3-Methyl-5-(p-tolyl)-1,4-ditosyl-1H-pyrazole (4x). The title compound was obtained as a white solid (173.7 mg, 72%). Mp 186–187 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.55 (d, $J = 8.0$ Hz, 2H), 7.34–7.23 (m, 4H), 7.19 (d, $J = 7.6$ Hz, 2H), 7.12 (d, $J = 7.6$ Hz, 2H), 6.98 (d, $J = 7.6$ Hz, 2H), 2.54 (s, 3H), 2.47 (s, 3H), 2.43 (s, 3H), 2.37 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.0, 148.2, 146.3, 144.2, 140.3, 138.6, 133.9, 130.5, 129.8, 129.3, 128.3, 128.1, 127.1, 124.0, 123.1, 21.6, 21.5, 21.4, 14.0; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{25}H_{24}N_2O_4S_2Na$: 503.1075; found: 503.1083.

5-(4-Methoxyphenyl)-3-methyl-1,4-ditosyl-1H-pyrazole (4y).^{14b} The title compound was obtained as a white solid (169.7 mg, 68%). Mp 211–213 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.53 (d, $J = 7.6$ Hz, 2H), 7.32–7.21 (m, 4H), 7.12 (d, $J = 7.2$ Hz, 2H), 7.01 (d, $J = 7.6$ Hz, 2H), 6.89 (d, $J = 7.6$ Hz, 2H), 3.90 (s, 3H), 2.55 (s, 3H), 2.42 (s, 3H), 2.36 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 161.0, 151.0, 148.2, 146.3, 144.2, 138.7, 134.0, 132.2, 129.9, 129.3, 128.3, 127.1, 124.1, 117.9, 112.8, 55.3, 21.7, 21.5, 14.1.

3-Methyl-5-(naphthalen-1-yl)-1,4-ditosyl-1H-pyrazole (4z). The title compound was obtained as a white solid (193.4 mg, 75%). Mp 200–203 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.98 (d, $J = 8.0$ Hz, 1H), 7.81 (d, $J = 8.4$ Hz, 1H), 7.52 (t, $J = 7.4$ Hz, 1H), 7.45–7.35 (m, 3H), 7.29–7.21 (m, 1H), 7.11 (d, $J = 7.6$ Hz, 2H), 7.08–6.99 (m, 3H), 6.76 (d, $J = 8.0$ Hz, 2H), 6.67 (d, $J = 8.8$ Hz, 1H), 2.68 (s, 3H), 2.36 (s, 3H), 2.12 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.0, 146.3, 145.8, 143.9, 137.5, 133.3, 132.6, 132.0, 130.7, 129.7, 129.5, 128.9, 128.5, 128.0, 127.1, 126.3, 125.7, 125.1, 124.9, 124.3, 123.8, 21.6, 21.2, 14.2; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{28}H_{24}N_2O_4S_2Na$: 539.1075; found: 539.1082.

5-(4-Fluorophenyl)-3-methyl-1,4-ditosyl-1H-pyrazole (4A). The title compound was obtained as a white solid (172.4 mg, 71%). Mp 177–180 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.54 (d, $J = 8.0$ Hz, 2H), 7.33–7.23 (m, 4H), 7.14 (d, $J = 7.6$ Hz, 2H), 7.11–7.03 (m, 4H), 7.15 (d, $J = 8.0$ Hz, 2H), 6.96 (d, $J = 8.4$ Hz, 2H), 2.55 (s, 3H), 2.44 (s, 3H), 2.38 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 163.8 (d, $J = 250.3$ Hz), 151.0, 146.7 (d, $J = 23.6$ Hz), 144.4, 138.5, 133.8, 132.8 (d, $J = 8.6$ Hz), 130.0, 129.4, 128.3, 127.0, 124.3, 122.1 (d, $J = 3.3$ Hz), 114.8, 114.6, 21.7, 21.4, 14.0; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{24}H_{21}N_2O_4S_2FNa$: 507.0824; found: 507.0836.

5-(4-Chlorophenyl)-3-methyl-1,4-ditosyl-1H-pyrazole (4B).^{14b} The title compound was obtained as a white solid (190.8 mg, 76%). Mp 189–191 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.56 (d, $J = 8.0$ Hz, 2H), 7.36 (d, $J = 8.0$ Hz, 2H), 7.34–7.24 (m, 4H), 7.15 (d, $J = 7.6$ Hz, 2H), 7.03 (d, $J = 8.4$ Hz, 2H), 2.55 (s, 3H), 2.44 (s, 3H), 2.38 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.2, 146.7, 146.6, 144.6, 138.5, 136.7, 133.8, 132.0, 130.0, 129.5, 128.4, 127.8, 127.1, 124.7, 124.1, 21.7, 21.5, 14.0.

5-(4-Bromophenyl)-3-methyl-1,4-ditosyl-1H-pyrazole (4C). The title compound was obtained as a white solid (203.3 mg, 74%). Mp 185–187 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.56 (d, $J = 8.0$ Hz, 2H), 7.52 (d, $J = 8.4$ Hz, 2H), 7.31 (d, $J = 8.4$ Hz, 2H), 7.28 (d, $J = 8.4$ Hz, 2H), 7.15 (d, $J = 8.0$ Hz, 2H), 6.96 (d, $J = 8.4$ Hz, 2H), 2.55 (s, 3H), 2.44 (s, 3H), 2.38 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.1, 146.6, 146.5, 144.5, 138.4, 133.7, 132.2, 130.7, 130.0, 129.5, 128.3, 127.1, 125.2, 124.9, 124.4, 21.7, 21.5, 13.9; HRMS (TOFMS) m/z $[M+H]^+$ calcd for $C_{24}H_{21}N_2O_4S_2Br$: 545.0204; found: 545.0204.

5-(3-Chlorophenyl)-3-methyl-1,4-ditosyl-1H-pyrazole (4D). The title compound was obtained as a white solid (166.5 mg, 66%). Mp 162–164 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.56 (d, $J = 7.2$ Hz, 2H), 7.48 (d, $J = 8.0$ Hz, 1H), 7.39–7.27 (m, 5H), 7.15 (d, $J = 7.2$ Hz, 2H), 7.05 (d, $J = 7.2$ Hz, 1H), 6.78 (s, 1H), 2.58 (s, 3H), 2.45 (s, 3H), 2.39 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.0, 146.7, 145.7, 144.6, 138.3, 133.7, 133.5, 130.3, 130.2, 130.1, 129.5, 128.9, 128.8, 128.4, 128.0, 127.2, 124.5, 21.7, 21.5, 14.0; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{24}H_{21}N_2O_4S_2ClNa$: 523.0529; found: 523.0540.

5-(Benzo[b]thiophen-2-yl)-3-methyl-1,4-ditosyl-1H-pyrazole (4E). The title compound was obtained as a white solid (168.4 mg, 65%). Mp 199–201 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.87–7.78 (m, 2H), 7.69 (d, $J = 7.6$ Hz, 2H), 7.49–7.36 (m, 4H), 7.27 (d, $J = 7.2$ Hz, 2H), 7.14 (s, 1H), 7.03 (d, $J = 7.6$ Hz, 2H), 2.57 (s, 3H), 2.43 (s, 3H), 2.32 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.2, 146.7, 144.5, 141.7, 140.4, 138.2, 137.9, 133.6, 130.0, 129.8, 129.4, 128.6, 127.4, 126.0, 125.6, 124.75, 124.72, 124.5, 122.0, 21.7, 21.5, 14.1; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{26}H_{22}N_2O_4S_3Na$: 545.0639; found: 545.0650.

3-Methyl-5-(thiophen-3-yl)-1,4-ditosyl-1H-pyrazole (4F). The title compound was obtained as a white solid (141.1 mg, 60%). Mp 206–208 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.51 (d, $J = 8.0$ Hz, 2H), 7.35–7.22 (m, 6H), 7.12 (d, $J = 8.0$ Hz, 2H), 6.86 (d, $J = 4.4$ Hz, 1H), 2.57 (s, 3H), 2.42 (s, 3H), 2.36 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.1, 146.5, 144.3, 143.3, 138.5, 133.8, 129.9, 129.7, 129.4,

128.3, 127.04, 124.8, 124.6, 124.4, 21.7, 21.5, 14.1; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{22}H_{20}N_2O_4S_3Na$: 495.0483; found: 495.0490.

5-(Furan-2-yl)-3-methyl-1,4-ditosyl-1H-pyrazole (4G). The title compound was obtained as a white solid (124.5 mg, 54%). Mp 194–196 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.75 (d, $J = 8.4$ Hz, 2H), 7.64–7.59 (m, 1H), 7.51 (d, $J = 8.0$ Hz, 2H), 7.32 (d, $J = 8.0$ Hz, 2H), 7.22 (d, $J = 8.0$ Hz, 2H), 6.72 (d, $J = 3.6$ Hz, 1H), 6.63–6.58 (m, 1H), 2.50 (s, 3H), 2.44 (s, 3H), 2.39 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.2, 146.6, 144.62, 144.56, 138.5, 137.5, 136.8, 133.7, 130.0, 129.6, 128.6, 127.2, 125.7, 116.3, 111.3, 21.7, 21.5, 13.9; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{22}H_{20}N_2O_5S_2Na$: 479.0711; found: 479.0717.

2-(3-Methyl-1,4-ditosyl-1H-pyrazol-5-yl)pyridine (4H). The title compound was obtained as a white solid (114.5 mg, 49%). Mp 196–198 °C.

1H NMR (400 MHz, $CDCl_3$) δ 8.75–8.70 (m, 1H), 7.88–7.80 (m, 3H), 7.57 (d, $J = 8.4$ Hz, 2H), 7.50–7.43 (m, 2H), 7.32 (d, $J = 8.0$ Hz, 2H), 7.22 (d, $J = 8.0$ Hz, 2H), 2.43 (s, 6H), 2.38 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.1, 148.8, 146.9, 146.43, 146.39, 144.4, 138.6, 135.6, 133.7, 130.0, 129.6, 128.8, 127.3, 126.6, 124.5, 123.7, 21.8, 21.5, 13.5; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{23}H_{21}N_3O_4S_2Na$: 490.0871; found: 490.0877.

4-((4-Chlorophenyl)sulfonyl)-3-methyl-5-phenyl-1-tosyl-1H-pyrazole (4I). The title compound was obtained as a white solid (152.1 mg, 62%). Mp 191–194 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.58–7.49 (m, 3H), 7.38 (t, $J = 7.8$ Hz, 2H), 7.32–7.23 (m, 6H), 7.04 (d, $J = 7.2$ Hz, 2H), 2.58 (s, 3H), 2.42 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 150.8, 147.9, 146.5, 139.8, 139.7, 133.6, 130.5, 130.2, 129.9, 128.9, 128.5, 128.3, 127.4, 125.9, 123.4, 21.6, 14.0; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{23}H_{19}N_2O_4S_2ClNa$: 509.0372; found: 509.0376.

4-((4-Fluorophenyl)sulfonyl)-3-methyl-5-phenyl-1-tosyl-1H-pyrazole (4J). The title compound was obtained as a white solid (136.8 mg, 58%). Mp 181–183 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.57–7.48 (m, 3H), 7.42–7.32 (m, 4H), 7.30–7.23 (m, 2H), 7.04 (d, $J = 7.6$ Hz, 2H), 6.96 (t, $J = 8.4$ Hz, 2H), 2.58 (s, 3H), 2.43 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 165.3 (d, $J = 254.5$ Hz), 150.9, 147.8, 146.5, 137.4 (d, $J = 3.4$ Hz), 133.7, 130.6, 130.3, 129.94 (d, $J = 9.8$ Hz), 129.93, 128.3, 127.5, 126.0, 123.6, 115.9 (d, $J = 22.1$ Hz), 21.7, 14.1; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{23}H_{19}N_2O_4S_2FNa$: 493.0668; found: 493.0674.

4-(Ethylsulfonyl)-3-methyl-5-phenyl-1-tosyl-1H-pyrazole (4K). The title compound was obtained as a white solid (128.7 mg, 64%). Mp 154–156 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.60–7.51 (m, 3H), 7.49–7.41 (m, 2H), 7.31–7.22 (m, 4H), 2.72 (q, $J = 7.2$ Hz, 2H), 2.53 (s, 3H), 2.44 (s, 3H), 1.14 (t, $J = 7.2$ Hz, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 151.8, 148.4, 146.6, 133.9, 130.60, 130.55, 130.0, 128.4, 127.7, 126.0, 120.8, 50.7, 21.6, 13.9, 6.9; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{19}H_{20}N_2O_4S_2Na$: 427.0762; found: 427.0769.

3-Methyl-5-phenyl-1-tosyl-4-((trifluoromethyl)sulfonyl)-1H-pyrazole (4L). The title compound was obtained as a white solid (53.3 mg, 24%). Mp 139–142 °C.

1H NMR (400 MHz, $CDCl_3$) δ 7.62 (d, $J = 8.4$ Hz, 2H), 7.57 (t, $J = 7.6$ Hz, 1H), 7.45 (t, $J = 7.8$ Hz, 2H), 7.32 (d, $J = 8.4$ Hz, 2H), 7.22 (d, $J = 7.6$ Hz, 2H), 2.53 (s, 3H), 2.46 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 153.0, 152.7, 147.2, 133.2, 130.8, 130.22, 130.18, 128.8, 127.5, 124.8, 119.6 (q, $J = 322.7$ Hz), 113.1, 21.8, 13.5; HRMS (TOFMS) m/z $[M + Na]^+$ calcd for $C_{18}H_{15}N_2O_4S_2F_3Na$: 467.0323; found: 467.0330.

Gram-Scale Reaction. To a 25 mL Schlenk tube were added 4-methylbenzenesulfonohydrazide (**1a**) (745 mg, 4.0 mmol), 1-phenylbutane-1,3-dione (**2d**) (779 mg, 4.8 mmol), sodium 4-methylbenzenesulfinate (**3b**) (1.43 g, 8.0 mmol), $K_2HPO_4 \cdot 3H_2O$ (730.6 mg, 3.2 mmol), I_2 (1.53 g, 6.0 mmol), and 12 mL of CH_3CN sequentially under air. Then, the tube was sealed and the reaction mixture was stirred at room temperature for 23 h. It was then

quenched (consumption of residual I_2) with saturated $Na_2S_2O_3$ solution, forming a white precipitate. Filtration of the suspension gave the crude product. Washing the crude product with water (100 mL) and petroleum ether (100 mL) sequentially afforded the pure product **4w** as a white solid (1.57 g, 84%).

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.joc.1c00171>.

1H NMR and ^{13}C NMR spectra (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Jinjiang Kuang – School of Pharmaceutical and Materials Engineering, Taizhou University, Taizhou 318000, P. R. China; Institute of Advanced Studies, Taizhou University, Taizhou 318000, P. R. China; orcid.org/0000-0002-7085-4023; Email: jinjiangkuang@163.com

Yongmin Ma – School of Pharmaceutical and Materials Engineering, Taizhou University, Taizhou 318000, P. R. China; Institute of Advanced Studies, Taizhou University, Taizhou 318000, P. R. China; Email: yongmin.ma@tzc.edu.cn

Authors

Jiawen Chen – School of Pharmaceutical and Materials Engineering, Taizhou University, Taizhou 318000, P. R. China

Dongwei Chen – School of Pharmaceutical and Materials Engineering, Taizhou University, Taizhou 318000, P. R. China

Complete contact information is available at: <https://pubs.acs.org/10.1021/acs.joc.1c00171>

Author Contributions

[§]Miss J.-W. Chen and D.-W. Chen contributed equally to this work.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was financially supported by the Natural Science Foundation of Zhejiang Province of China (Grant No. LQ20B020008), Cultivation project of Taizhou University, and the Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (No. 2019R01005).

■ DEDICATION

Dedicated to the cherished memory of Dr. Negish.

■ REFERENCES

- (1) (a) Bekhit, A. A.; Hymete, A.; Bekhit, A. E.-D. A.; Damtew, A.; Aboul-Enein, H. Y. Pyrazoles as Promising Scaffold for the Synthesis of Anti-Inflammatory and/or Antimicrobial Agent: A Review. *Mini-Rev. Med. Chem.* **2010**, *10*, 1014–1033. (b) Küçükgüzel, S. G.; Senkardes, S. Recent Advances in Bioactive Pyrazoles. *Eur. J. Med. Chem.* **2015**, *97*, 786–815. (c) Khan, M. F.; Alam, M. M.; Verma, G.; Akhtar, W.; Akhter, M.; Shaquiquzzaman, M. The Therapeutic Voyage of Pyrazole and Its Analogs: A Review. *Eur. J. Med. Chem.* **2016**, *120*, 170–201. (d) Ansari, A.; Ali, A.; Asif, M.; Shamsuzzaman, S. Review: Biologically Active Pyrazole Derivatives. *New J. Chem.* **2017**, *41*, 16–41. (e) Xu, Z.; Gao, C.; Ren, Q. C.; Song, X. F.; Feng,

L. S.; Lv, Z. S. Recent Advances of Pyrazole-Containing Derivatives as Anti-Tubercular Agents. *Eur. J. Med. Chem.* **2017**, *139*, 429–440. (f) Faria, J. V.; Vegi, P. F.; Miguita, A. G. C.; dos Santos, M. S.; Boechat, N.; Bernardino, A. M. R. Recently Reported Biological Activities of Pyrazole Compounds. *Bioorg. Med. Chem.* **2017**, *25*, 5891–5903.

(2) Sowmya, D. V.; Teja, G. L.; Padmaja, A.; Prasad, V. K.; Padmavathi, V. Green approach for the synthesis of thiophenyl pyrazoles and isoxazoles by adopting 1,3-dipolar cycloaddition methodology and their antimicrobial activity. *Eur. J. Med. Chem.* **2018**, *143*, 891–898.

(3) (a) Sun, H.-Y.; Ji, F.-Q. A Molecular Dynamics Investigation on the Crizotinib Resistance Mechanism of C1156Y Mutation in ALK. *Biochem. Biophys. Res. Commun.* **2012**, *423*, 319–324. (b) Sau, M. C.; Rajesh, Y.; Mandal, M.; Bhattacharjee, M. Copper catalyzed regioselective N-alkynylation of pyrazoles and evaluation of the anticancer activity of ethynyl-pyrazoles. *ChemistrySelect* **2018**, *3*, 3511–3515.

(4) Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpiperazine Class of Cyclooxygenase-2 Inhibitors: Identification of 4-(4-Methylphenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl Benzenesulfonamide (Sc-58635, Celecoxib). *J. Med. Chem.* **1997**, *40*, 1347–1365.

(5) Li, J.; Huo, H.; Guo, R.; Liu, B.; Li, L.; Dan, W.; Xiao, X.; Zhang, J.; Shi, B. Facile and efficient access to androst-17-(1',3',4')-pyrazoles and androst-17 β -(1',3',4')-pyrazoles via vilmsieier reagents, and their antiproliferative activity evaluation in vitro. *Eur. J. Med. Chem.* **2017**, *130*, 1–14.

(6) Cravedi, J. P.; Deloux, G.; Zalko, D.; Viguie, C.; Debrauwer, L. Disposition of Fipronil in Rats. *Chemosphere* **2013**, *93*, 2276–2283.

(7) Durgamma, S.; Muralikrishna, A.; Padmavathi, V.; Padmaja, A. Synthesis and antioxidant activity of amido-linked benzoxazolyl/benzothiazolyl/benzimidazolyl-pyrroles and pyrazoles. *Med. Chem. Res.* **2014**, *23*, 2916–2929.

(8) (a) Mykhailiuk, P. K. Fluorinated Pyrazoles: From Synthesis to Applications. *Chem. Rev.* **2021**, *121*, 1670–1715. (b) da Rosa, B. N.; Venzke, D.; Poletti, T.; de Lima, N. P. K.; Camacho, J. T.; Mariotti, K. C.; dos Santos, M. A. Z.; pizzuti, L.; Carreno, N. L. V.; Pereira, C. M. P. Microwave Assisted Synthesis of Thiocarbamoylpyrazoles and Application as an Alternative Latent Fingerprint Developers. *J. Braz. Chem. Soc.* **2020**, *31*, 1327–1331.

(9) For some recent reports, see: (a) Despotopoulou, C.; Klier, L.; Knochel, P. Synthesis of fully substituted pyrazoles via regio- and chemoselective metalations. *Org. Lett.* **2009**, *11*, 3326–3329. (b) Neumann, J. J.; Suri, M.; Glorius, F. Efficient Synthesis of Pyrazoles: Oxidative C–C/N–N Bond-Formation Cascade. *Angew. Chem., Int. Ed.* **2010**, *49*, 7790–7794. (c) Chen, B.; Zhu, C.; Tang, Y.; Ma, S. Copper-mediated pyrazole synthesis from 2, 3-allenoates or 2-alkynoates, amines and nitriles. *Chem. Commun.* **2014**, *50*, 7677–7679. (d) Sun, J.; Qiu, J. K.; Zhu, Y. L.; Guo, C.; Hao, W. J.; Jiang, B.; Tu, S. J. Metal-Free Iodine-Catalyzed Synthesis of Fully Substituted Pyrazoles and Its Sulphenylation. *J. Org. Chem.* **2015**, *80*, 8217–8224. (e) Shao, Y.; Zheng, H.; Qian, J.; Wan, X. In Situ Generation of Nitrilimines from Aryldiazonium Salts and Diazo Esters: Synthesis of Fully Substituted Pyrazoles under Room Temperature. *Org. Lett.* **2018**, *20*, 2412–2415. (f) Wang, Q.; He, L.; Li, K. K.; Tsui, G. C. Copper-Mediated Domino Cyclization/Trifluoromethylation/Deprotection with TMSCF₃: Synthesis of 4-(Trifluoromethyl)pyrazoles. *Org. Lett.* **2017**, *19*, 658–661. (g) Tanimoto, K.; Ohkado, R.; Iida, H. Aerobic Oxidative Sulphenylation of Pyrazolones and Pyrazoles Catalyzed by Metal-Free Flavin–Iodine Catalysis. *J. Org. Chem.* **2019**, *84*, 14980–14986. (h) Tu, K. N.; Kim, S.; Blum, S. A. Copper-Catalyzed Aminoboration from Hydrazones To Generate Borylated Pyrazoles. *Org. Lett.* **2019**, *21*, 1283–1286. (i) Mao, X.; Ni, J.; Xu, B.; Ding, C. K₂S₂O₈-promoted direct thiocyanation of pyrazolin-5-ones

with ammonium thiocyanate at room temperature. *Org. Chem. Front.* **2020**, *7*, 350–354.

(10) For selected examples, see: (a) Wolf, W. M. The fungicidal activity of β -keto sulfones. Molecular conformation of α -phenylhydrazono- β -ketosulfones as determined by an X-ray analysis. *J. Mol. Struct.* **1999**, *474*, 113–124. (b) Petrov, K. G.; Zhang, Y.; Carter, M.; Cockerill, G. S.; Dickerson, S.; Gauthier, C. A.; Guo, Y.; Mook, R. A.; Rusnak, D. W.; Walker, A. L.; Wood, E. R.; Lackey, K. E. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 4686–4691. (c) Ettari, R.; Nizi, E.; Di Francesco, M. E.; Dude, M.-A.; Pradel, G.; Vicik, R.; Schirmeister, T.; Micale, N.; Grasso, S.; Zappala, M. Development of Peptidomimetics with a Vinyl Sulfone Warhead as Irreversible Falcipain-2 Inhibitors. *J. Med. Chem.* **2008**, *51*, 988–996. (d) Kotha, S.; Chavan, A. S. Design and Synthesis of Benzosultine-sulfone as a *o*-Xylylene Precursor via Cross-enyne Metathesis and Rongalite: Further Expansion to Polycyclics via Regioselective Diels–Alder Reaction. *J. Org. Chem.* **2010**, *75*, 4319–4322.

(11) Reviews: (a) Prilezhaeva, E. N. Sulfones and sulfoxides in the total synthesis of biologically active natural compounds. *Russ. Chem. Rev.* **2000**, *69*, 367–408. (b) Jacob, C. A scent of therapy: pharmacological implications of natural products containing redox-active sulfur atoms. *Nat. Prod. Rep.* **2006**, *23*, 851–863. (c) Khanum, F.; Anilakumar, K.; Viswanathan, K. Anticarcinogenic Properties of Garlic: A Review. *Crit. Rev. Food Sci. Nutr.* **2004**, *44*, 479–488. (d) *Biological Interactions of Sulfur Compounds*; Renwick, A. G.; Mitchell, S., Eds.; Taylor & Francis: London, U.K, 1996; p 42.

(12) (a) Kanishchev, O. S.; Bandera, P. Y.; Timoshenko, M. V.; Rusanov, B. E.; But, S. A.; Shermolovich, Y. G. Synthesis of 5-polyfluoroalkyl-4-(*p*-tolyl-sulfonyl)pyrazoles and 4-polyfluoroalkyl-5-(*p*-tolylsulfonyl)pyrimidines from 1-dimethylamino-2-(*p*-tolylsulfonyl)-polyfluoro-1-alken-3-ones. *Chem. Heterocycl. Compd.* **2007**, *43*, 887. (b) Gao, D.; Zhai, H.; Parvez, M.; Back, T. G. 1,3-Dipolar Cycloadditions of Acetylenic Sulfones in Solution and on Solid Supports. *J. Org. Chem.* **2008**, *73*, 8057. (c) Kumar, R.; Namboothiri, I. N. N. Regioselective Synthesis of Sulfonylpyrazoles via Base Mediated Reaction of Diazosulfones with Nitroalkenes and a Facile Entry into Withasomnine. *Org. Lett.* **2011**, *13*, 4016–4019. (d) Kumar, R.; Verma, D.; Mobin, S. M.; Namboothiri, I. N. N. One-Pot, Two-Step Conversion of Aldehydes to Phosphonyl- and Sulfonylpyrazoles Using Bestmann–Ohira Reagent. *Org. Lett.* **2012**, *14*, 4070–4073. For 1,3-sulfonyl shift and intramolecular cyclization affording sulfonated pyrazoles, see: (e) Zhu, Y.; Lu, W.-T.; Sun, H.-C.; Zhan, Z.-P. Lewis Base Catalyzed Synthesis of Multisubstituted 4-Sulfonyl-1H-Pyrazole Involving a Novel 1,3-Sulfonyl Shift. *Org. Lett.* **2013**, *15*, 4146–4149.

(13) Shermolovich, Y. G.; Emets, S. V. Sulfur-containing spirocyclic compounds based on 3-methyl-(amino)-1-phenylpyrazol-5-ones. *Chem. Heterocycl. Compd.* **2000**, *36*, 152–156.

(14) (a) Zhang, J.; Shao, Y.; Wang, H.; Luo, Q.; Chen, J.; Xu, D.; Wan, X. Dual roles of sulfonyl hydrazides: a three-component reaction to construct fully substituted pyrazoles using TBAI/TBHP. *Org. Lett.* **2014**, *16*, 3312–3315. (b) Guo, Y.; Wang, G.; Wei, L.; Wan, J.-P. Domino C–H Sulfonylation and Pyrazole Annulation for Fully Substituted Pyrazole Synthesis in Water Using Hydrophilic Enaminones. *J. Org. Chem.* **2019**, *84*, 2984–2990. (c) Tian, L.; Wan, J.-P.; Sheng, S. Transition Metal-free C–H Sulfonylation and Pyrazole Annulation Cascade for the Synthesis of 4-Sulfonyl Pyrazoles. *ChemCatChem.* **2020**, *12*, 2533–2537.

(15) Wei, W.; Cui, H.; Yang, D.; Liu, X.; He, C.; Dai, S.; Wang, H. Metal-free molecular iodine-catalyzed direct sulfonylation of pyrazolones with sodium sulfonates leading to sulfonated pyrazoles at room temperature. *Org. Chem. Front.* **2017**, *4*, 26–30.

(16) The ¹H NMR and ¹³C NMR spectra of compound 4u are consistent with those of compound 4a in ref 14a, the structure of which was confirmed by single-crystal X-ray analysis.

(17) (a) Liu, L. K.; Chi, Y.; Jen, K.-Y. Copper-catalyzed additions of sulfonyl iodides to simple and cyclic alkenes. *J. Org. Chem.* **1980**, *45*,

406–410. (b) Katrun, P.; Mueangkaew, C.; Pohmakotr, M.; Reutrakul, V.; Jaipetch, T.; Soorukram, D.; Kuhakarn, C. Regioselective C2 Sulfonylation of Indoles Mediated by Molecular Iodine. *J. Org. Chem.* **2014**, *79*, 1778–1785. (c) Wei, W.; Liu, C.; Yang, D.; Wen, J.; You, J.; Wang, H. Metal-Free Direct Construction of Sulfonamides via Iodine-Mediated Coupling Reaction of Sodium Sulfinates and Amines at Room Temperature. *Adv. Synth. Catal.* **2015**, *357*, 987–992.

(18) Yang, F.-L.; Ma, X.-T.; Tian, S.-K. Oxidative Mizoroki–Heck-Type Reaction of Arylsulfonyl Hydrazides for a Highly Regio- and Stereoselective Synthesis of Polysubstituted Alkenes. *Chem. Eur. J.* **2012**, *18*, 1582–1585.

(19) (a) Bai, Y.; Chen, W.; Chen, Y.; Huang, H.; Xiao, F.; Deng, G.-J. Copper-catalyzed oxidative cyclization of arylamides and β -diketones: new synthesis of 2,4,5-trisubstituted oxazoles. *RSC Adv.* **2015**, *5*, 8002–8005. (b) Inagaki, S.; Saito, K.; Suto, S.; Aihara, H.; Sugawara, A.; Tamura, S.; Kawano, T. Synthesis of 5-Aryl-3(2H)-furanones Using Intramolecular Cyclization of Sulfonium Salts. *J. Org. Chem.* **2018**, *83*, 13834–13846.